Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 13/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 13/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.31 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.31 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20601972 | 0.86 | HDAC1 (0.36) | HDAC1HDAC2ALDH1A1LMNAMAPT | |
| SCHEMBL2409030 | 0.82 | LMNA (0.35) | ALDH1A1LMNAKMT2ASMN1; SMN2EHMT2 | |
| SCHEMBL17283454 | 0.81 | HDAC1 (0.43) | HDAC1HDAC2ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL110223 | 0.79 | ALDH1A1 (0.46) | HDAC1HDAC2ALDH1A1LMNAMAPT | |
| SCHEMBL1120092 | 0.78 | ALDH1A1 (0.43) | HDAC1HDAC2ALDH1A1MAPTKMT2A | |
| SCHEMBL29459657 | 0.78 | ALDH1A1 (0.43) | HDAC1HDAC2ALDH1A1MAPTKMT2A | |
| SCHEMBL906682 | 0.77 | ALDH1A1 (0.41) | HDAC1HDAC2ALDH1A1LMNAMAPT | |
| SCHEMBL17758942 | 0.77 | ALDH1A1 (0.39) | HDAC1HDAC2ALDH1A1LMNAMAPT | |
| SCHEMBL2033141 | 0.77 | ALDH1A1 (0.48) | ALDH1A1LMNAMAPTKMT2ASMN1; SMN2 | |
| SCHEMBL11927655 | 0.77 | EHMT2 (0.40) | HDAC1HDAC2ALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3188761-A1 | METHODS FOR FORMULATING ANTIBODY DRUG CONJUGATE COMPOSITIONS | ImmunoGen, Inc. (US) | 2017-07-12 | — | — | EP | claimed |
| WO-2016036861-A1 | METHODS FOR FORMULATING ANTIBODY DRUG CONJUGATE COMPOSITIONS | IMMUNOGEN, INC. (US) | 2016-03-10 | — | — | WO | claimed |
| EP-2694106-A2 | METHODS FOR INCREASING EFFICACY OF FOLR1 CANCER THERAPY | Immunogen, Inc. (US) | 2014-02-12 | — | — | EP | claimed |
| WO-2012138749-A1 | METHODS FOR DECREASING OCULAR TOXICITY OF ANTIBODY DRUG CONJUGATES | IMMUNOGEN, INC. (US) | 2012-10-11 | — | — | WO | claimed |
| WO-2012135675-A2 | METHODS FOR INCREASING EFFICACY OF FOLR1 CANCER THERAPY | IMMUNOGEN, INC. (US) | 2012-10-04 | — | — | WO | claimed |
| EP-4347661-A1 | TREATMENT OF CANCER IN PATIENTS WITH SOLUBLE FR-ALPHA | ImmunoGen, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| WO-2023137156-A2 | T CELL MODULATORY POLYPEPTIDES WITH CONJUGATION SITES AND METHODS OF USE THEREOF | CUE BIOPHARMA, INC. (US) | 2023-07-20 | — | — | WO | disclosed |
| WO-2023137158-A2 | T CELL MODULATORY POLYPEPTIDES WITH CONJUGATION SITES AND METHODS OF USE THEREOF | CUE BIOPHARMA, INC. (US) | 2023-07-20 | — | — | WO | disclosed |
| WO-2022256507-A1 | TREATMENT OF CANCER IN PATIENTS WITH SOLUBLE FR-ALPHA | IMMUNOGEN, INC. (US) | 2022-12-08 | — | — | WO | disclosed |
| WO-2021158780-A1 | SELF-ASSEMBLING PRODRUGS AS IMMUNE BOOSTERS FOR CANCER IMMUNOTHERAPY | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-08-12 | — | — | WO | disclosed |
| EP-3624839-A1 | ANTI-CD33 IMMUNOCONJUGATE DOSING REGIMENS | Immunogen, Inc. (US) | 2020-03-25 | — | — | EP | disclosed |
| EP-3442554-A1 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS ASSOCIATED WITH NEOVASCULARIZATION | Iconic Therapeutics, Inc. (US) | 2019-02-20 | — | — | EP | disclosed |
| EP-2544719-A1 | CD37-BINDING MOLECULES AND IMMUNOCONJUGATES THEREOF | Immunogen, Inc. (US) | 2013-01-16 | — | — | EP | disclosed |
| EP-2538976-A1 | FOLATE RECEPTOR 1 ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREOF | Immunogen, Inc. (US) | 2013-01-02 | — | — | EP | disclosed |
| WO-2012135740-A2 | CD37-BINDING MOLECULES AND IMMUNOCONJUGATES THEREOF | IMMUNOGEN, INC. (US) | 2012-10-04 | — | — | WO | disclosed |
| WO-2012078868-A1 | METHODS FOR THE PREPARATION OF CHARGED CROSSLINKERS | IMMUNOGEN, INC. (US) | 2012-06-14 | — | — | WO | disclosed |
| WO-2012058592-A2 | NON-ANTAGONISTIC EGFR-BINDING MOLECULES AND IMMUNOCONJUGATES THEREOF | IMMUNOGEN, INC. (US) | 2012-05-03 | — | — | WO | disclosed |
| WO-2012019024-A2 | HER3-BINDING MOLECULES AND IMMUNOCONJUGATES THEREOF | IMMUNOGEN, INC. (US) | 2012-02-09 | — | — | WO | disclosed |
| WO-2011112978-A1 | CD37-BINDING MOLECULES AND IMMUNOCONJUGATES THEREOF | IMMUNOGEN, INC. (US) | 2011-09-15 | — | — | WO | disclosed |
| WO-2011106528-A1 | FOLATE RECEPTOR 1 ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREOF | IMMUNOGEN, INC. (US) | 2011-09-01 | — | — | WO | disclosed |